Breaking News Instant updates and real-time market news.

TLRY

Tilray

$154.99

34.79 (28.94%)

, MOC

Command Security

$1.90

0.08 (4.40%)

09:02
09/19/18
09/19
09:02
09/19/18
09:02

Fly Intel: Pre-market Movers

HIGHER: Tilray (TLRY), up 48% following CEO Brendan Kennedy's appearance last night on Jim Cramer's Mad Money... Command Security (MOC), up 46% after signing a definitive agreement to be acquired by Prosegur SIS, a wholly-owned subsidiary of Prosegur, for $2.85 in cash per share... SunPower (SPWR), up 7% after receiving a solar tariff exclusion... Juniper (JNPR), up 2% after Nomura Instinet analyst Jeffrey Kvaal upgraded the stock to Buy from Neutral and raised his price target for the shares to $34 from $28. The analyst believes Juniper "will finally be able to catch the webscale capex growth tailwind in 2019."... Aerpio (ARPO), up 2% after Guggenheim analyst Adnan Butt started the stock with a Buy rating and $10 price target... MGM Resorts (MGM), up 1.5% after the New York Post reported that Starboard Value took at least a $500M stake in the casino chain. LOWER: LyondellBasell (LYB), down 2.5% after JPMorgan analyst Jeffrey Zekauskas downgraded the stock to Underweight from Neutral and lowered his price target for the shares to $95 from $110. Consensus expectations have the company facing a "shallow trough" in petrochemical pricing leading to flat to lower consolidated EBITDA in 2019, Zekauskas tells investors... G1 Therapeutics (GTHX), down 9% after a 3M share secondary priced at $60.00 per share... Novartis (NVS), down 1% after the U.K.'s National Institute for Health and Care Excellence said it "encourages further discussions on Kymriah for adult lymphoma," but in draft guidance, NICE says "CAR-T is too expensive to recommend as a treatment for adults with lymphoma."... Resolute Forest (RFP), down 1% after the stock was downgraded to Neutral from Outperform at CIBC.

TLRY

Tilray

$154.99

34.79 (28.94%)

MOC

Command Security

$1.90

0.08 (4.40%)

SPWR

SunPower

$7.55

0.97 (14.74%)

JNPR

Juniper

$28.60

0.6 (2.14%)

ARPO

Aerpio Pharmaceuticals

$3.77

0.155 (4.29%)

MGM

MGM Resorts

$27.59

0.17 (0.62%)

LYB

LyondellBasell

$102.16

-1.3 (-1.26%)

GTHX

G1 Therapeutics

$62.94

-3.41 (-5.14%)

RFP

Resolute Forest

$14.65

0.125 (0.86%)

  • 20

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

  • 11

    Oct

  • 16

    Oct

  • 27

    Nov

  • 19

    Sep

TLRY Tilray
$154.99

34.79 (28.94%)

09/06/18
09/06/18
DOWNGRADE

Market Perform
Tilray downgraded to Market Perform after 'massive' move up at Northland
As previously reported, Northland analyst Mike Grondahl downgraded Tilray to Market Perform from Outperform. While he continues to see the company playing a "huge role" in the recreational-use cannabis market in Canada and other countries and the medical market in Europe, he also believes the risk/reward is far more balanced following the recent "massive" move in the stock. Though he lowered his rating, Grondahl also sees optionality for Tilray from other new markets, including potentially the U.S. someday, he noted.
09/06/18
NORL
09/06/18
DOWNGRADE
NORL
Market Perform
Tilray downgraded to Market Perform from Outperform at Northland
08/29/18
08/29/18
DOWNGRADE
Target $54

Neutral
Tilray downgraded to Neutral on valuation at Roth Capital
As previously reported, Roth Capital analyst Charles Finnie downgraded Tilray (TLRY) to Neutral from Buy, citing valuation, noting that the stock has advanced nearly 2.5 times since going public last month. While Tilray reported strong results and "appears to be on track for a very impressive 2019," Finnie believes the stock's current levels reflect "a highly speculative M&A scenario" following Constellation's (STZ) $4B investment in market leader Canopy Growth (CGC), he tells investors. Though he cut his rating, Finnie raised his price target on Tilray shares to $54 from $35.
09/06/18
09/06/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ANALYSTS WEIGH IN ON MICRON: Despite recent softness in DRAM spot pricing, the more appropriate metric for Micron Technology (MU) investors to focus on is gross margin, Deutsche Bank analyst Sidney Ho said. On gross margin, the analyst sees Micron benefiting from "solid cost improvement through technology transition" in fiscal 2019. Further, he believes the DRAM market has become more diverse, which should help offset temporary weakness in any given end market. As the company continues to execute on its technology roadmap and delivers solid operating results, Ho expects Micron's stock valuation to re-rate. He kept a Buy rating and $80 price target on Micron. However, Baird analyst Tristan Gerra said Micron is no longer a top large-cap idea, citing its valuation and the likelihood gross margins may be nearing their peak. He also noted DRAM pricing is likely peaking and NAND is in significant oversupply. Gerra maintained an Outperform rating but lowered his price target to $75 from $100 on Micron shares. ARGUS UPGRADES PG&E TO BUY: Argus analyst Jacob Kilstein upgraded PG&E (PCG) to Buy from Hold with a price target of $54, saying the company's recent California legislative victory will reduce its liability for last year's wildfire as its earnings outlook improves. Kilstein further anticipates PG&E to announce a timeline regarding its dividend reinstatement after being forced to suspend its quarterly payout on concerns about its potential wildfire damage responsibility estimated as high as $12B. NORTHLAND DOWNGRADES TILRAY TO MARKET PERFORM: Northland analyst Mike Grondahl downgraded Tilray (TLRY) to Market Perform from Outperform. While he continues to see the company playing a "huge role" in the recreational-use cannabis market in Canada and other countries and the medical market in Europe, he also believes the risk/reward is far more balanced following the recent "massive" move in the stock. JPMORGAN CUTS FRANKLIN RESOURCES TO UNDERWEIGHT: JPMorgan analyst Kenneth Worthington downgraded Franklin Resources (BEN) to Underweight from Neutral and lowered his price target for the shares to $29 from $32. The analyst believes the more recent weakness in emerging markets, and in particular in emerging market debt, will weigh on both Franklin's organic growth and earnings potential. He thinks challenges in emerging markets put additional pressure on "an already challenging growth story characterized by weak fund performance, significant outflows, and declining margins." Worthington continues to have a negative view on the asset management sector.
MOC Command Security
$1.90

0.08 (4.40%)

SPWR SunPower
$7.55

0.97 (14.74%)

09/19/18
ROTH
09/19/18
NO CHANGE
ROTH
Buy
Tariff exemption a 'meaningful positive' for SunPower, Enphase, says Roth
Roth Capital analyst Philip Shen tells investors in a research note that SunPower's (SPWR) exclusion from the 30% Section 201 import tariffs for its IBC cells and modules is a "meaningful positive" for the company, as with the exclusion, SunPower appears to be the only company to serve the U.S. resi market with tariff-free modules imported from outside the U.S., except for First Solar (FSLR), which does not serve the resi market. In addition, Shen views the news as a meaningful positive for Enphase (ENPH) given its exclusive relationship with SunPower, and says Enphase could benefit from increased volumes ahead.
09/19/18
JPMS
09/19/18
NO CHANGE
Target $9
JPMS
Neutral
JPMorgan 'warming to' SunPower story after tariff exemption
JPMorgan analyst Paul Coster raised his price target for SunPower (SPWR) to $9.00 from $8.50 after the company announced that its request for Section 201 tariff exemption has been granted by the United States Trade Representative's office. The news is positive as it eliminates an overhang for the stock and provides the company a competitive advantage over international competitors, Coster tells investors in a research note. He now believes SunPower's guidance, which assumes that the tariffs remain in place, has upside. The analyst maintains a Neutral rating on SunPower but is "warming to the story." Coster also believes the news is a "mild negative" for First Solar (FSLR).
09/19/18
FBCO
09/19/18
UPGRADE
Target $10
FBCO
Outperform
SunPower upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Michael Weinstein upgraded SunPower to Outperform from Neutral and raised his target price for shares to $10 from $8. In a research note to investors, Weinstein says the news that its interdigitated back contact solar modules manufactured in Malaysia will be exempted from U.S. import tariffs won't impact 2018 earnings, as the decision doesn't explicitly call out retroactiveness, but sees a benefit to 2019 and 2020 gross profit of $35M-$40M per year vs. prior estimates. Weinstein says the exemption removes the near-term tariff overhang for SunPower and the company is on course to exit non-core asset sales, delever and pivot to higher margin and less capital intensive NGT modules and DG markets.
09/19/18
BARD
09/19/18
NO CHANGE
Target $9
BARD
Neutral
SunPower given Fresh Pick designation at Baird
Baird analyst Ben Kallo is naming SunPower as a Fresh Pick ahead of its Q3 earnings call as he thinks management could provide a favorable update following the exemption from the Section 201 tariffs. The analyst believes this should enable the company to better compete in the U.S. market while capturing higher margins. Kallo maintained his Neutral rating and raised his price target to $9 from $7 on SunPower shares.
JNPR Juniper
$28.60

0.6 (2.14%)

09/19/18
NOMU
09/19/18
UPGRADE
Target $34
NOMU
Buy
Nomura upgrades Juniper to Buy on routing recovery, other growth drives
Nomura Instinet analyst Jeffrey Kvaal upgraded Juniper Networks to Buy from Neutral and raised his price target for the shares to $34 from $28. The analyst believes Juniper "will finally be able to catch the webscale capex growth tailwind in 2019." He expects the company to recover from its webscale routing "annus horribilis," gain share in webscale switching, and continue its enterprise growth. Kvaal expects webscale capital expenditures to rise 40% in 2018 and he lifted his 2019 sales estimate for Juniper to 5%.
07/30/18
07/30/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Buy from Neutral at BofA/Merrill with analyst David Barden saying he is positive on AT&T's 20-year low P/E multiple, Timer Warner (TWX) merger benefits of earnings accretion and expanding cash, favorable emerging wireless business trends, and a call option on value extraction from the merger of AT&T's distribution network with Time Warner's content and ad inventory. 2. American Airlines (AAL) upgraded to Outperform from Neutral at Macquarie. 3. Avis Budget (CAR) upgraded to Buy from Neutral at Northcoast. 4. Cabot Oil & Gas (COG) upgraded to Positive from Neutral at Susquehanna with analyst Biju Perincheril citing the recent weakness in the shares but he also feels the risk/reward is attractive with many projects providing production growth over the next two years along with accelerating free cash flow generation. 5. Juniper (JNPR) upgraded to Buy from Hold at Deutsche Bank with analyst Vijay Bhagavath saying he's "going against the grain" and making a "contrarian call." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/18
NOMU
09/19/18
UPGRADE
Target $34
NOMU
Buy
Juniper upgraded to Buy from Neutral at Nomura Instinet
Nomura Instinet analyst Jeffrey Kvaal upgraded Juniper Networks to Buy and raised his price target for the shares to $34 from $28.
07/30/18
07/30/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA UPGRADES AT&T TO BUY: Bank of America Merrill Lynch upgraded AT&T (T) to Buy from Neutral as analyst David Barden is positive on AT&T's 20-year low P/E multiple, Timer Warner merger benefits, favorable emerging wireless business trends, and a call option on value extraction from the merger of AT&T's distribution network with Time Warner's content and ad inventory. He keeps a $37 price target on AT&T shares. DEUTSCHE UPS JUNIPER IN 'CONTRARIAN' CALL: Deutsche Bank analyst Vijay Bhagavath upgraded Juniper Networks (JNPR) to Buy from Hold and raised his price target for the shares to $32 from $25. The analyst said he's "going against the grain" and making a "contrarian call." The post-earnings selloff on the "better than feared" Q2 results and below consensus Q3 guidance, which is primarily related to switch router upgrade timing at a handful of cloud and service provider customers, provides a "reasonable entry point." He believes "robust" switch router and next generation security refresh cycles will start in fiscal 2019 and that Juniper's fundamentals will improve from FY19 through FY21. STIFEL CUTS SYNCHRONOS TO SELL: Stifel analyst Tom Roderick downgraded Synchronoss (SNCR) to Sell from Hold, stating that recent filings reveal that liquidity issues loom, the company is "out of levers, and time is not on their side." The turnaround required to keep the company from fundraising "feels Herculean," added Roderick, who lowered his price target on Synchronoss shares to $3 from $8. BUCKINGHAM SAYS FORCED SALE OF CHARTER ASSETS 'UNLIKELY': Buckingham analyst Matthew Harrigan noted that New York's Public Service Commission has moved to push Charter (CHTR) out of the state and presented the company with a 60 day ultimatum to find a buyer for its assets there due to what it views as "repeated failures" to honor its commitments around the 2016 merger with Time Warner Cable. While he thinks an extended court battle seems "virtually certain," Harrigan does not see much likelihood of any forced disposition of its New York State assets. He keeps a Buy rating and $397 price target on Charter shares.
ARPO Aerpio Pharmaceuticals
$3.77

0.155 (4.29%)

09/19/18
GUGG
09/19/18
INITIATION
Target $10
GUGG
Buy
Aerpio Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim analyst Adnan Butt, started Aerpio Pharmaceuticals with a Buy rating and $10 price target. The analyst believes the company's AKB-9778, being evaluated in a Phase 2b study in patients with non-proliferative diabetic retinopathy, has differentiating attributes and utility in multiple complications. He sees clinical and pre-clinical evidence of AKB-9778 improving measures of retinopathy and nephropathy.
07/23/18
NEED
07/23/18
INITIATION
Target $10
NEED
Buy
Aerpio Pharmaceuticals initiated with a Buy at Needham
Needham analyst Chad Messer initiated Aerpio with a Buy rating and a price target of $10, citing the company's development of AKB-9778, which is "a subcutaneously administered Tie2 activator for non proliferative diabetic retinopathy, or NPDR, and other complications of diabetes." The analyst states that NPDR is an underserved area of medical need, since the "intravitreal anti-VEGF inhibitors labeled for this often asymptomatic but progressive condition are too costly and burdensome". Messer further notes that he is optimistic about the company's positive phase 2b readout for AKB-9778 expected in Q2 of 2019.
07/02/18
HCWC
07/02/18
NO CHANGE
Target $9
HCWC
Buy
Aerpio target lowered to $9 after out-licensing of AKB-4924 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Aerpio Pharmaceuticals to $9 after the company completed a $45M financing and out-licensed AKB-4924 to Gossamer Bio. The analyst estimates Aerpio could have roughly $70M in cash as of mid-2018, providing operating capital to 2020. He reiterates a Buy rating on the shares.
04/18/18
HCWC
04/18/18
INITIATION
Target $10
HCWC
Buy
Aerpio Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Aerpio Pharmaceuticals with a Buy rating and $10 price target. The company is reinventing diabetic eye therapy, Selvaraju tells investors in a research note. The analyst notes Aerpio's lead candidate, AKB-9778, is a small molecule selective activator of Tie2 signaling pathway and is being investigated in a Phase 2b trial for non-proliferative diabetic retinopathy.
MGM MGM Resorts
$27.59

0.17 (0.62%)

09/10/18
NOMU
09/10/18
NO CHANGE
NOMU
Nomura sees attractive risk/rewards among Macau gaming stocks
Since early June, the Macau gaming stock prices have fallen 20%-30%, with much of the decline over the last five trading days, Nomura Instinet analyst Harry Curtis tells investors in a research note titled with a Billy Ray Valentine quote: "'They're Panicking Out There.'" The group is down to multiples last seen in 2015 when VIP revenues compressed 40%, the analyst points out. He believes the group's risk/reward profiles are as attractive as it was three years ago. Positive comments about gross gaming revenue trends made on Q2 earnings calls "HAVE NOT deteriorated," writes Curtis. He believes Macau gaming stocks should be bought at these levels, especially Melco Resorts & Entertainment (MLCO), MGM Resorts (MGM) and Wynn Resorts (WYNN).
09/14/18
NOMU
09/14/18
NO CHANGE
NOMU
Nomura sees 'vastly different' picture in Macau than stock selloff suggests
Nomura Instinet analyst Harry Curtis says his latest conversations with Macau operators Melco Resorts & Entertainment (MLCO), MGM Resorts (MGM) and Wynn Resorts (WYNN) paint a picture that is "vastly different" from the recent share selloff in the space. The analyst believes quarter-to-date trends through early September "remain strong." Operators have not seen any incremental weakness since reporting Q2 results, Curtis tells investors in a research note. Further, based on recent checks and conversations with management, he believes the strength that Wynn Resorts was seeing when it reported Q2 earnings on August 1 has not deteriorated. The analyst keeps a Buy rating on all three companies.
08/21/18
NOMU
08/21/18
NO CHANGE
NOMU
Buy
Room survey suggests 'modest' upside to guidance for MGM, Caesars, says Nomura
Nomura Instinet analyst Harry Curtis said in a research note to investors that while his latest Las Vegas room rate survey shows "mostly negative" y/y trends through October, sequential price momentum, measured by first-to-last call rates, has become more positive for Strip operators for the first time in months. Curtis says the latest survey for Q3 shows y/y rates down 1.2% for MGM (MGM) vs. guidance of down 5%-7% and up 3.6% for Caesars (CZR) vs. guidance of flat to up 2%, suggesting there could be modest upside to Q3 guidance for both MGM and Caesars. The analyst has a Buy rating on both stocks.
08/15/18
MSCO
08/15/18
NO CHANGE
MSCO
Morgan Stanley more bullish on Wynn Resorts after Vegas meetings
After holding meetings in Las Vegas, Morgan Stanley analyst Thomas Allen said he came away feeling that commentary mostly supports a "decent" Vegas market, which "should be enough" for MGM Resorts (MGM). The meetings also made him more bullish on Wynn Resorts (WYNN), as Allen believes weaker Macau growth and lost share should be transitory issues, he tells investors. Allen has Overweight ratings on Las Vegas Sands (LVS) and MGM and an Equal Weight rating on Wynn Resorts.
LYB LyondellBasell
$102.16

-1.3 (-1.26%)

09/19/18
JPMS
09/19/18
DOWNGRADE
Target $95
JPMS
Underweight
JPMorgan downgrades LyondellBasell to Underweight amid rising feedstock costs
JPMorgan analyst Jeffrey Zekauskas downgraded LyondellBasell to Underweight from Neutral and lowered his price target for the shares to $95 from $110. Consensus expectations have the company facing a "shallow trough" in petrochemical pricing leading to flat to lower consolidated EBITDA in 2019, Zekauskas tells investors in a research note. The analyst, however, believes the recent sharp rise in feedstock costs for Lyondell, particularly due to the rise in the price of ethane, alters this view. He believes raw material volatility undermines confidence in LyondellBasell's business forecasts for 2019 and that this uncertainty "will lead to a somewhat lower trading multiple."
09/17/18
SBSH
09/17/18
DOWNGRADE
Target $109
SBSH
Neutral
LyondellBasell downgraded to Neutral from Buy at Citi
Citi analyst P.J. Juvekar downgraded LyondellBasell to Neutral with a reduced price target of $109. The current rise in ethane is likely to persist until Q2 of 2019, Juvekar tells investors in a research note. The analyst thinks there may be a better entry point for LyondellBasell over the next few quarters "as the margin squeeze plays out."
09/17/18
09/17/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Visa (V) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst James Schneider citing recent share out-performance. 2. Hormel Foods (HRL) downgraded to Market Perform from Outperform at BMO Capital with analyst Kenneth Zaslow citing valuation. 3. Costco (COST) downgraded to Equal Weight from Overweight at Barclays with analyst Karen Short citing valuation. 4. LyondellBasell (LYB) downgraded to Neutral from Buy at Citi with analyst P.J. Juvekar saying the current rise in ethane is likely to persist until Q2 of 2019. 5. Revance (RVNC) downgraded to Market Perform from Outperform at JMP Securities with analyst Donald Ellis citing Botox study data released by Allergan (AGN). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/18
JPMS
09/19/18
DOWNGRADE
Target $95
JPMS
Underweight
LyondellBasell downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded LyondellBasell to Underweight and lowered his price target for the shares to $95 from $110.
GTHX G1 Therapeutics
$62.94

-3.41 (-5.14%)

09/18/18
NEED
09/18/18
NO CHANGE
Target $76
NEED
Buy
G1 Therapeutics price target raised to $76 from $60 at Needham
Needham analyst Chad Messer raised his price target on G1 Therapeutics to $76 and kept his Buy rating, citing the company's announcement yesterday of amended phase 2 trial protocol for trilaciclib testing in combination with chemotherapy and Tecentrq. The analyst believes that the myelopreservation data from this trial "may help bolster the available dataset" that the company is planning to bring to the FDA in the first half of 2019 for discussion regarding a viable path to approval. Messer adds that he looks forward to the "updated data from the randomized frontline SCLC trial of trilaciclib at ESMO in October".
09/17/18
HCWC
09/17/18
NO CHANGE
Target $79
HCWC
Buy
G1 Therapeutics price target raised to $79 from $61 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for G1 Therapeutics to $79 saying the company, in his opinion, makes positive revision to its Phase 2 protocol in newly diagnosed small cell lung cancer patients. The analyst views the earlier availability of comprehensive myelopreservation data as a positive that could add substantially to discussions with regulators in early 2019. Following the announcement of the revised protocol, White has increased confidence in the approval of trilaciclib. He keeps a Buy rating on G1 Therapeutics.
09/10/18
BTIG
09/10/18
INITIATION
Target $80
BTIG
Buy
G1 Therapeutics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed G1 Therapeutics with a Buy rating and a price target of $80, citing the company's "unique" position of potentially developing two "best in class" CDK4/6 inhibitors - trilaciclib and lerociclib. The analyst notes that trilaciclib's positive outcomes support its efficacy and looks ahead to the 2nd line SCLC data later this year. Shrader adds that while the stock is no longer cheap, having risen nearly 400% since its IPO, "significant upside" in the stock price remains thanks to the "large market opportunity" of both programs that he estimates to be around $2B by 2025.
05/29/18
HCWC
05/29/18
INITIATION
Target $61
HCWC
Buy
G1 Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White started G1 Therapeutics with a Buy rating and $61 price target. The company's trilaciclib could improve patient outcomes by maximizing the beneficial effects of chemotherapy, while minimizing myelosuppression and immunosuppression, White tells investors in a research note. He believes investors are missing the potential of trilaciclib, which he thinks become part of the standard of care for patients with CDK4/6-independent tumors, including small cell lung cancer and triple-negative breast cancer, that receive chemotherapy.
RFP Resolute Forest
$14.65

0.125 (0.86%)

09/19/18
CIBC
09/19/18
DOWNGRADE
Target $420
CIBC
Neutral
Resolute Forest downgraded to Neutral from Outperformer at CIBC
07/11/18
CIBC
07/11/18
UPGRADE
CIBC
Outperformer
Resolute Forest upgraded to Outperformer from Neutral at CIBC
08/30/18
08/30/18
NO CHANGE

Resolute Forest to sell recycled pulp mill in Fairmont, West Virginia, for $55M
Resolute Forest has entered into a definitive asset purchase agreement with ND Paper, a subsidiary of Nine Dragons Paper, for the sale of its Fairmont, West Virginia, recycled bleached kraft pulp mill, for $55M plus certain elements of working capital, payable in cash. Nine Dragons is primarily engaged in the production and sale of a broad variety of packaging paperboard products. In addition to nine paper mills operating in Asia, Nine Dragons, through its wholly-owned subsidiary ND Paper, also operates two U.S.-based facilities in Wisconsin and Maine. ND Paper has agreed to offer employment to Fairmont mill employees, effective upon closing of the transaction, which is expected within the next two months.
05/23/18
SCOT
05/23/18
UPGRADE
SCOT
Sector Perform
Resolute Forest upgraded to Sector Perform from Underperform at Scotiabank

TODAY'S FREE FLY STORIES

PFE

Pfizer

$44.50

0.48 (1.09%)

12:56
10/21/18
10/21
12:56
10/21/18
12:56
Hot Stocks
Pfizer presents overall survival data from PALOMA-3 trial of Ibrance »

Pfizer announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:52
10/21/18
10/21
12:52
10/21/18
12:52
Hot Stocks
Merck presents early data for STING agonist in advanced solid tumors/lymphomas »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:47
10/21/18
10/21
12:47
10/21/18
12:47
Hot Stocks
Dynavax's SD-101, Keytruda combo still shows 70% ORR in Advanced Melanoma »

Dynavax (DVAX) presented…

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

12:44
10/21/18
10/21
12:44
10/21/18
12:44
Hot Stocks
Exelixis announces results from data analysis of CABOSUN, METEOR trials »

Exelixis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 01

    Nov

  • 07

    Nov

  • 27

    Nov

  • 14

    Jan

AGEN

Agenus

$1.97

-0.025 (-1.26%)

12:39
10/21/18
10/21
12:39
10/21/18
12:39
Hot Stocks
Agenus presents clinical data on PD-1, CTLA-4 at ESMO 2018 »

Agenus presented updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

OMED

OncoMed

$2.47

-0.17 (-6.44%)

12:37
10/21/18
10/21
12:37
10/21/18
12:37
Hot Stocks
OncoMed announces interim phase 1b results for Navicixizumab, Paclitaxel combo »

OncoMed Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:34
10/21/18
10/21
12:34
10/21/18
12:34
Hot Stocks
ImmunoGen presents initial data from FORWARD II expansion cohort »

ImmunoGen (IMGN)…

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 02

    Nov

  • 11

    Jan

  • 16

    Feb

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

12:30
10/21/18
10/21
12:30
10/21/18
12:30
Hot Stocks
Opdivo, Yervoy combo shows promising results in advanced form of bladder cancer »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:26
10/21/18
10/21
12:26
10/21/18
12:26
Hot Stocks
Merck's Keytruda shows complete response rate of nearly 40% in high-risk NMIBC »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

12:18
10/21/18
10/21
12:18
10/21/18
12:18
Hot Stocks
Tesaro presents Phase 1 GARNET data of TSR-042 in MSI-H endometrial cancer »

Tesaro summarized updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 07

    Nov

UDR

UDR, Inc.

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
UDR, Inc. rating change at Evercore ISI »

UDR, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 07

    Nov

AVB

AvalonBay

$178.01

1.725 (0.98%)

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
AvalonBay rating change  »

AvalonBay downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
Morgan Stanley China hardware analyst to hold analyst/industry conference call »

China Hardware Tech…

BIIB

Biogen

$319.85

-10.4 (-3.15%)

14:57
10/20/18
10/20
14:57
10/20/18
14:57
Conference/Events
Biogen to host conference call »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

14:13
10/20/18
10/20
14:13
10/20/18
14:13
Conference/Events
Selecta Biosciences to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TROV

Trovagene

$1.12

-0.03 (-2.61%)

14:11
10/20/18
10/20
14:11
10/20/18
14:11
Conference/Events
Trovagene to host conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLS

Sellas Life Sciences

$1.56

-0.24 (-13.33%)

13:54
10/20/18
10/20
13:54
10/20/18
13:54
Conference/Events
Sellas Life Sciences to host conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 07

    Nov

NVS

Novartis

$87.19

0.95 (1.10%)

13:50
10/20/18
10/20
13:50
10/20/18
13:50
Conference/Events
Novartis to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

UA

Under Armour

$16.79

-0.365 (-2.13%)

, UAA

Under Armour

$18.20

-0.42 (-2.26%)

12:43
10/20/18
10/20
12:43
10/20/18
12:43
Periodicals
Under Armour stock could triple, Barron's says »

Under Armour has had a…

UA

Under Armour

$16.79

-0.365 (-2.13%)

UAA

Under Armour

$18.20

-0.42 (-2.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 30

    Oct

  • 27

    Nov

  • 03

    Mar

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

, CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

12:37
10/20/18
10/20
12:37
10/20/18
12:37
Periodicals
Constellation Brands changing CEOs, not marijuana strategy, Barron's says »

Constellation Brands…

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 14

    Nov

CFG

Citizens Financial

$36.36

1.44 (4.12%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:33
10/20/18
10/20
12:33
10/20/18
12:33
Periodicals
Citizens Financial stock worth buying, Barron's says »

Citizens Financial (CFG)…

CFG

Citizens Financial

$36.36

1.44 (4.12%)

AAPL

Apple

$219.28

3.3 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.95

-1 (-0.65%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:26
10/20/18
10/20
12:26
10/20/18
12:26
Periodicals
Netflix emerged as winner in new way to rank big tech stocks risk, Barron's says »

A year ago,…

FB

Facebook

$153.95

-1 (-0.65%)

AAPL

Apple

$219.28

3.3 (1.53%)

AMZN

Amazon.com

$1,763.91

-7.54 (-0.43%)

NFLX

Netflix

$332.69

-14.02 (-4.04%)

GOOG

Alphabet

$1,096.41

8.51 (0.78%)

GOOGL

Alphabet Class A

$1,104.66

7.43 (0.68%)

DIS

Disney

$118.81

2.55 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 03

    Mar

BABA

Alibaba

$142.90

1.1 (0.78%)

, TCEHY

Tencent

$0.00

(0.00%)

12:17
10/20/18
10/20
12:17
10/20/18
12:17
Periodicals
Chinese internet giants down, not out, Barron's says »

Alibaba (BABA), Tencent…

BABA

Alibaba

$142.90

1.1 (0.78%)

TCEHY

Tencent

$0.00

(0.00%)

BIDU

Baidu

$191.93

0.1 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 02

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.